Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp417 | Osteoporosis: treatment | ECTS2013

A case of atypical femoral fracture with abnormal cortical bone characterized by impaired mineralization and pyrophosphate accumulation

Shabestari Maziar , Eriksen Erik Fink , Roschger Paul , Paschalis Eleftherios , Diez-Perez Adolfo

Impaired bone material properties have been invoked as being responsible for the development of atypical femoral fractures (AFF) after long term bisphosphonate use. We therefore analyzed bone material properties in a bone biopsy obtained at the fracture site from an 88-year-old female with AFF, who had been treated with alendronate for 8 years. We used conventional histology, quantitative backscattered electron imaging (qBEI), and Raman spectroscopy (RS).<p class="abstext"...

ba0001pp456 | Other diseases of bone and mineral metabolism | ECTS2013

Altered bone material properties in HLA-B27 rats, an animal model for arthritis, ankylosing spondylitis, and gastrointestinal inflammation

Gamsjaeger Sonja , Paschalis Eleftherios P. , Zoehrer Ruth , Klaushofer Klaus , Tatakis Dimitris N.

HLA-B27 transgenic rats, developed by inserting into rat genome the gene for HLA-B27, a human Class I major histocompatibility molecule involved in antigen presentation, spontaneously develop arthritis, ankylosing spondylitis, gastrointestinal inflammation, and severe alveolar bone loss, among other signs of a generalized inflammatory response. Clinical manifestations in these rats closely resemble features of HLA-B27–associated diseases in humans. More recently, investig...

ba0003pp359 | Osteoporosis: treatment | ECTS2014

Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study

Hassler Norbert , Gamsjaeger Sonja , Hofstetter Birgit , Brozek Wolfgang , Misof Barbara , Roschger Paul , Klaushofer Klaus , Paschalis Eleftherios

Bisphosphonates (BPs) including alendronate (ALN) are the most widely prescribed therapy for post-menopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, concerns have been expressed lately regarding potential detrimental effects due to prolonged bone turnover reduction, although no definite cause–effect relationship has been established to date. The purpose of the present study was to determine bone material quality by R...

ba0003pp388 | Other diseases of bone and mineral metabolism | ECTS2014

Late onset presentation of osteogenesis imperfecta with additional mutation on GNAS gene: case report

Stathopoulos Konstantinos D , Koromila Theodora , Paschalis Eleftherios P , Soultanis Konstantinos , Atsali Erato , Bournazos Ilias , Damianou Eirini , Zoubos Aristides B , Papaggelopoulos Panagiotis J , Skarantavos Grigoris

Aim: We present the case of a 36y female patient with multiple fragility fractures after the age of 21 and mutations in COL1A1, COL1A2 and GNAS genes.Material and methods: A 36y female patient with multiple fractures of the axial and appendicular skeleton was referred to us for consultation. The patient was born with hexadactyly of the left foot and had a history of mild thoracolumbar scoliosis (10°) and medium height (165 cm) with no other history ...